Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cure Lab, Inc.
A protein sequence associated with Huntington's disease may become life-saving vaccine component
June 24th, 2008
On June 10, 2008 the scientific journal "Vaccine" published a paper by the Massachusetts based biotech company Cure Lab, Inc., demonstrating that a protein sequence important in neurodegenerative Huntington's disease can be safely used as a new generation of vaccine adjuvants. The major component of every vaccine is an antigen that elicits specific immunity to a particular virus, bacteria or even cancer cells. Search for better antigens is one of the most pressing medical and public health necessities, and the biotech industry invests heavily in this research. However, antigens are able to generate a limited immune response if administered alone. In order to be...
Source: Cancer Weekly (2008-06-24)
|
